Biography
Christian is responsible for driving business development and incubation in adjacent fields and white spaces at Siemens Healthineers. Christian and his team evaluate opportunities, trigger investments in start-ups, and drive partnership projects – with a particular focus on the field of precision medicine. Christian also serves on the board of associations and start-up companies focusing on precision medicine. Christian brings more than 15 years of experience in new business development and has successfully incubated a variety of new products, developed strategies for leading global companies, and is the (co)-inventor of assorted patent families. He is driven by his passion to bridge the chasm between innovative ideas and the commercialization of new technologies.

Biography
Sebastian Kronmueller incubates startup businesses within Healthineers with a focus on novel molecular applications. His current incubation businesses include the Siemens Healthcare Laboratory in Berkeley, California and NEO New Oncology in Cologne, Germany. Previously he led the execution of strategic initiatives as Head of Special Projects for Siemens Healthineers, playing an instrumental role in shaping the strategy of Siemens Healthineers in preparation for the IPO planned in 2018. Before this role he led a project management team for companion diagnostics and software development and was responsible for the carve-out and divestment of the Healthineers Microbiology business. He began his career as strategy consultant with Siemens Management Consulting. Sebastian holds a graduate degree in physics from Ludwig-Maximilians-University in Munich, Germany and a graduate certificate in Management Science and Engineering from Stanford University in Palo Alto, California.

Biography
With over 30 years of healthcare experience, Dale Newman currently focuses on Precision Medicine through the development and marketing of AI-driven Clinical Pathways Solutions (https://www.siemens-healthineers.com/en-us/digital-health-solutions/digital-solutions-overview/clinical-decision-support/ai-pathway-companion) that utilize augmented intelligence, data integration, and insights from cohort analytics to support providers, patients, and other stakeholders as they strive to manage the diagnosis and treatment of highly complex diseases. Ms. Newman’s earlier healthcare career focused on direct patient care as a Registered Critical Care Respiratory Therapist and Cardiac Service Line Administrator. Her passion for creating solutions to optimize the delivery of high quality, cost-effective patient care led her to industry where she has focused on the application of informatics and advanced technologies in information technology, imaging, and medical device companies, consulting firms, and group purchasing organizations.

Biography
Oliver Rinner is co-founder and CEO of Biognosys, a Swiss proteomics technology company. He spun off the company in 2008 from the lab of Prof. Ruedi Aebersold at the ETH Zurich where he co-invented the basic technology for next-generation proteomics, which Biognosys applies today for large scale protein sequencing in clinical samples. Over the last 11 years Oliver raised several rounds of financing from institutional and corporate investors to develop the technology further with the goal to enable deep protein-level data acquisition for data-driven medicine. Oliver graduated from the University of Tubingen with a Master in Psychology and Biochemistry. He received his Ph.D. from the ETH Zurich for his work in behavioral molecular genetics.

Biography
Dr. Sung is an Associate Professor of Radiology, where his research primarily focuses on the development of novel medical imaging methods and artificial intelligence using magnetic resonance imaging (MRI). He received a Ph.D. degree in Electrical Engineering from the University of Southern California, Los Angeles, in 2008, and from 2008 to 2012, he finished his postdoctoral training at Stanford in the Departments of Radiology. He joined the University of California, Los Angeles (UCLA) Department of Radiological Sciences, in 2012. His research interest is to develop fast and reliable magnetic resonance imaging (MRI) techniques that can provide improved diagnostic contrast and useful information. In particular, his research group (https://mrrl.ucla.edu/sunglab/) is currently focused on developing advanced deep learning algorithms and quantitative MRI techniques for early diagnosis, treatment guidance, and therapeutic response assessment for oncologic applications. Such developments can offer more robust and reproducible measures of biologic markers associated with human cancers.